Home > Back to Publisher > Report Information

The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)

Kalorama Information
October 1, 2009
250 Pages - SKU: KLI2435380

Attention: There is an updated edition available for this report.

Abstract Table of Contents Search inside this report Related Reports

Countries covered: Global

The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to them.

This Kalorama Information The World Market for Anti-Infectives considers the anti-infective drug market as it faces challenges with resistance and generic competition. The report focuses on three key segments of treatment:

Antifungals (Allylamines, Azoles,Polyene Macrolides and Other Antifungals)
Antibacterials (Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Carbopenems, Miscellaneous)

Antivirals (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors)

For each category and each subsegment, current market and forecast is provided. The report covers both currently marketed and late stage development products.. Revenues for each segment were generated using dollar sales for each product.

The report includes statistical information for infections by type worldwide, with special emphasis on the U.S. and Europe. As part of its coverage the report provides:

Overview
Description of Products on the Market
Review of Products in Late Stage Development
Market Estimates and Forecasts
Competitive Analysis of Leading Providers
Regional Breakdown of Antifungal, Antibacterial and Antiviral Market (US, Europe and Asia)
Market Share of Antifungal, Antibacterial and Antiviral Market

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals focused on the anti-infective industry. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

Additional Information

New York, October 1, 2009 - Drug resistance is a key public health problem and also a problem for makers of branded antibacterial products, according to the findings of a new report. Traditional antibiotics: quinolones, cephalosporins, and penicillins, have seen their market share erode due to loss of effectiveness, while at the same time they are facing heavy generic competition. Growth is flat and in some cases, sales are declining, according to healthcare market research publisher Kalorama Information’s Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals). The total world market for antibacterial drugs, which represents almost half of the anti-infectives market, is estimated at $24.5 billion for 2009, up a scant 0.7% from 2008.

Resistance is not a new concept - resistances to antimicrobials were first recognized around 1950 starting with penicillin. However, the problem is increasing at an alarming rate that far exceeds the rate at which new drugs are being discovered and brought to market. Therefore, notes Kalorama Information, preserving the effectiveness of existing antibiotics is critical to protecting public health.

“As much as half of medically prescribed antibiotics are unnecessary, which is a remnant of the misinformation that antibiotics cure all and are not harmful,” said Melissa Elder, an analyst for Kalorama Information. “In many hospitals, third generation cephalosporins are used in emergency rooms when the existence of infections has not even been established. Many such interventions are of questionable efficacy and pose an additional risk in favor of resistant bacteria.”

More than 90% of staphylococcus aureus strains are resistant to penicillin and other related antibiotics; and many are resistant even to the newer methicillin-related drugs. There is an alarming rise in the incidence of enterococci (the streptococcus that is the most common cause of hospital-acquired infections) resistant to the antibiotic vancomycin, often the last weapon for defeating these pathogens.

“Concerns over resistance have resulted in additional funding for new treatments specifically targeting resistant bacteria,” said Elder. “Although this seems to be a solution on the surface, many developers are reluctant to follow this development path.”

For more information on the anti-infectives market, see Kalorama Information’s Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) which covers both currently marketed and late stage development products. The report includes statistical information for infections by type worldwide, with special emphasis on the U.S. and Europe, market estimates and forecasts, and competitive analysis of leading providers.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.

CHAPTER ONE: EXECUTIVE SUMMARY

Introduction
Scope and Methodology
Total Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

Overview
Introduction to Pathogens
Demographics of the World
Anti-Infective Drug Resistance
- Antibiotic Abuse
- Antibiotic Use in Agriculture
- Resistance in Select Populations
- Children
- The Elderly
- Compromised Individuals
- Measures for Reducing Resistance
- Antibiotic Cycling
- Antibiotic Education
- Screening Hospitalized patients
HIV Trends
- Infection Rates
- HIV and Women
- Costs and Funding of HIV Treatment
- Access to HIV/AIDS Treatment
Manufacturer and Marketer Trends
- Trends in Partnerships and Alliances
- Developers Trends
- Trends in Rx-to-OTC Switches

CHAPTER THREE: ANTIFUNGAL DRUGS

Overview
Types of Fungal Infections
- Superficial
- Systemic
- Histoplasmosis
- Coccidioidomycosis
- Blastomycosis
- Fungal Infection Statistics
- Fungal Infection Risk
Description of Antifungal Products
- Systemic Antifungals
- Allylamines
- Azoles
- Polyene Macrolides
- Systemic Miscellaneous Antifungals
- Topical Antifungals
- Allylamines
- Topical Azoles
- Topical Polyene Macrolides
- Topical Miscellaneous Antifungals
Market Overview
Total Market Size and Forecast
Antifungal Market by Product Type
- Allylamines
- Azoles
- Polyene Macrolides
- Other Antifungals
Antifungal Market by Geographical Region
Market Analysis by Treated Condition
Competitive Analysis

CHAPTER FOUR: ANTIBACTERIAL DRUGS

Overview
Classification of Antibacterial Organisms
Antimicrobial Spectrum
Bacterial Resistance
Principles of Anti-bacterial Therapy
- Infecting Organism
- Antibiotic Sensitivity Testing
- Site of Infection
- Host Defenses and Organ Function
- Antibiotic Pharmacokinetics
- Monitoring Therapy
Combination Therapy and Prophylactic Use
Bacterial Infection Statistics
Bacterial Infection Risk
Description of Antibacterial Products
- Cephalosporins
- Macrolides
- Penicillins
- Quinolones
- Sulfonamides
- Tetracyclines
- Carbopenems
- Systemic Miscellaneous Antibiotics
Market Overview
Total Market Size and Forecast
Antibacterial Market by Product Type
Cephalosporins
Macrolides
Penicillins
Quinolones
Sulfonamides
Tetracyclines
Carbopenems
Other Products
Antibacterial Market by Geographical Region
Market Analysis by Treated Condition
Competitive Analysis
Leading Products

CHAPTER FIVE: ANTIVIRAL DRUGS

Overview: Introduction to Viruses
Examples of Pathogenic Viruses
Virus Function and Life History
Replication in DNA Viruses
Replication of RNA Viruses
Replication in Retroviruses
Host Defenses Against Viruses
Viral Ploys to Invade Host Cells and Circumvent Host Responses
- Invasion of Host Cells
- Subversion of the Immune Response
- Avoidance of Immune Detection and Attack by Killer Cells
HIV and AIDS
Viral Infection Statistics
Description of Antivirals Products
- Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors
- Nucleoside Reverse Transcriptase Inhibitors
- Combination Nucleoside Reverse Transcriptase Inhibitors
- Nucleotide Analogue Reverse Transcriptase Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Combination Non-Nucleoside Reverse Transcriptase Inhibitors
- DNA Polymerase Inhibitors
Protease Inhibitors
Other Antivirals
Market Overview
Total Market Size and Forecast
- Antiviral Market by Product Type
- Nucleoside Analogs
- Protease Inhibitors
- Other Antivirals
Antiviral Market by Geographical Region
Market Analysis by Treated Condition
Competitive Analysis
Leading Products

CHAPTER SIX: MARKET SUMMARY

Total Market Size and Forecast
Market by Segment

CHAPTER SEVEN: CORPORATE PROFILES

Introduction
Abbott Laboratories
AstraZeneca/MedImmune
Bayer Schering Pharma AG
Bristol-Myers Squibb
Daiichi Sankyo
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson Group
Merck & Co.
Novartis
Pfizer
Roche
Schering-Plough Corporation
Wyeth

APPENDIX: LIST OF MAJOR PROVIDERS

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1: The Global Market for Anti-Infectives by Product Segment, 2006-2013
Figure 1-1: The Global Market for Anti-Infectives by Product Segment, 2009

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

Table 2-1: Estimated World Population by Age and Geographical Region, 2009
Figure 2-1: Estimated World Population by Age and Geographical Region, 2009
Table 2-2: Worldwide HIV/AIDS Infections
Table 2-3: Women Living with HIV/AIDS, by Region 1990 to 2007 (Percent)
Table 2-4: AIDS Resource Needs (US$ billion), 2006-2008
Table 2-5: Antiretroviral Access for HIV Infected Individuals by Region, 2005*
Table 2-6: Anti-Infective Drugs in Development by Developer
Table 2-7: Anti-infectives Ingredients Transferred from Rx-to-OTC

CHAPTER THREE: ANTIFUNGAL DRUGS

Table 3-1: Estimated World and U.S. Incidence of Fungal Infections
Figure 3-1: Estimated World and U.S. Incidence of Leading Fungal Infections
Table 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009
Figure 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009
Table 3-3: Systemic Allylamines
Table 3-4: Systemic Azoles
Table 3-5: Systemic Polyene Macrolides
Table 3-6: Systemic Miscellaneous Antifungals
Table 3-7: Topical Allylamines
Table 3-8: Topical Azoles
Table 3-9: Topical Polyene Macrolides
Table 3-10: Topical Miscellaneous Antifungals
Table 3-11: The World Market for Antifungal Drugs 2006-2013
Figure 3-3: The World Market for Antifungal Drugs 2006-2013
Table 3-12: Antifungal Drug Market by Type 2006-2013
Figure 3-4: The World Market for Antifungal Drugs Revenues by Type 2006-2013
Figure 3-5: The World Market for Antifungal Drugs Revenues by Type 2009 and 2013
Table 3-13: The World Market for Antifungal Drugs Estimated Products Sales by Geographic Region 2006-2013
Figure 3-6: The World Market for Antifungal Drugs Estimated Product Sales by Geographic Region 2006-2013
Table 3-14: World Antifungal Market Estimated Products Sales by Infection Type, Sales in Millions, 2009
Figure 3-7: World Antifungal Market Estimated Distribution of Products Sales by Infection Type, 2009
Table 3-15: World Market for Antifungal Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009
Figure 3-8: World Market for Antifungal Drugs Estimated Revenues of Leading Suppliers 2006-2009
Figure 3-9: World Market for Antifungal Drugs Estimated Market Share of Leading Suppliers, 2009
Table 3-16: World Market for Antifungal Drugs Estimated Sales of Select Products 2006-2009
Figure 3-10: World Market for Antifungal Drugs Estimated Sales of Select Products 2006-2009

CHAPTER FOUR: ANTIBACTERIAL DRUGS

Table 4-1: Antibiotics with Difficult Penetration
Table 4-2: Estimated World and U.S. Incidence of Bacterial Infections
Figure 4-1: Estimated World and U.S. Incidence of Bacterial Infections
Table 4-3: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009
Figure 4-2: World Population at Risk for Serious Bacterial Infections Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009
Table 4-4: Currently Available Cephalosporin Antibiotics (Type, Brand, and Manufacturer)
Table 4-5: Currently Available Macrolide Antibiotics (Type, Brand, and Manufacturer)
Table 4-6: Currently Available Penicillin Antibiotics (Type, Brand, and Manufacturer)
Table 4-6: Currently Available Penicillin Antibiotics (Type, Brand, and Manufacturer)
Table 4-7: Currently Available Quinolone Antibiotics (Type, Brand, and Manufacturer)
Table 4-8: Currently Available Sulfonamide Antibiotics (Type, Brand, and Manufacturer)
Table 4-9: Currently Available Tetracycline Antibiotics (Type, Brand, and Manufacturer)
Table 4-10: Currently Available Carbopenems (Type, Brand, and Manufacturer)
Table 4-11: Currently Available Other Miscellaneous Antibiotics (Type, Brand, and Manufacturer)
Table 4-12: The World Market for Antibacterial Drugs 2006-2013
Figure 4-3: The World Market for Antibacterial Drugs 2006-2013
Table 4-13: Antibacterial Drug Market by Type 2006-2013
Figure 4-4: The World Market for Antibacterial Drugs Revenues by Type 2006-2013
Figure 4-5: The World Market for Antibacterial Drugs Revenues by Type 2009 and 2013
Table 4-14: The World Market for Antibacterial Drugs Estimated Products Sales by Geographic Region 2006-2013
Figure 4-6: The World Market for Antibacterial Drugs Estimated Product Sales by Geographic Region 2006-2013
Table 4-17: World Antibacterial Market Estimated Products Sales by Infection Type
Figure 4-7: World Antibacterial Market Estimated Distribution of Products Sales by Infection Type, 2009
Table 4-18: World Market for Antibacterial Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009
Figure 4-8: World Market for Antibacterial Drugs Estimated Revenues of Leading Suppliers 2006-2009
Figure 4-9: World Market for Antibacterial Drugs Estimated Market Share of Leading Suppliers, 2009
Table 4-19: World Market for Antibacterial Drugs Estimated Sales of Select Products 2006-2009
Figure 4-10: World Market for Antibacterial Drugs Estimated Sales of Top Ten Products 2006-2009

CHAPTER FIVE: ANTIVIRAL DRUGS

Table 5-1: Host Cell Receptors
Table 5-2: Estimated World and U.S. Incidence of Viral Infections
Figure 5-1: Estimated World and U.S. Incidence of Leading Viral Infections
Table 5-3: Currently Available Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
Table 5-4: Currently Available Combination Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
Table 5-5: Currently Available Nucleotide Analog Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
Table 5-6: Currently Available Non-Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
Table 5-7: Currently Available Combination Non-Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
Table 5-8: Currently Available DNA Polymerase Inhibitors (Type, Brand, and Manufacturer)
Table 5-9: Currently Available Protease Inhibitors (Type, Brand, and Manufacturer)
Table 5-10: Currently Available Miscellaneous Antivirals (Type, Brand, and Manufacturer)
Table 5-11: The World Market for Antiviral Drugs 2006-2013
Figure 5-2: The World Market for Antiviral Drugs 2006-2013
Table 5-12: Antiviral Drug Market by Type 2006-2013
Figure 5-3: The World Market for Antiviral Drugs Revenues by Type 2006-2013
Figure 5-4: The World Market for Antiviral Drugs Revenues by Type 2009 and 2013
Table 5-13: The World Market for Antiviral Drugs Estimated Products Sales by Geographic Region 2006-2013
Figure 5-5: The World Market for Antiviral Drugs Estimated Product Sales by Geographic Region 2006-2013
Table 5-14: World Antiviral Market Estimated Products Sales by Infection Type
Figure 5-6: World Antiviral Market Estimated Distribution of Products Sales by Infection Type, 2009
Table 5-15: World Market for Antiviral Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009
Figure 5-7: World Market for Antiviral Drugs Estimated Revenues of Leading Suppliers 2006-2009
Figure 5-8: World Market for Antiviral Drugs Estimated Market Share of Leading Suppliers, 2009
Table 5-16: World Market for Antiviral Drugs Estimated Sales of Top Products 2006-2009
Figure 5-9: World Market for Antiviral Drugs Estimated Sales of Top Products 2006-2009

CHAPTER SIX: MARKET SUMMARY

Table 6-1: The Global Market for Anti-Infectives by ProductSegment, 2006-2013
Figure 6-1: The World Market for Anti-Infective Drugs 2006-2013
Figure 6-2: The Global Market for Anti-Infectives by Product Segment, 2009
Figure 6-3: The Global Market for Anti-Infectives by Product Segment, 2013

More Global Infectious Diseases Reports

2012 World Infectious Disease Testing Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country by Venture Planning Group
This report provides a worldwide overview of the infectious disease testing market environment, structure, size and growth. Includes estimates of the number of laboratories ...

2012 Global Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies by Venture Planning Group
The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers ...

Global Infectious Disease Treatment Market 2011-2014 by Infiniti Research Limited
TechNavio’s analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 8.1 percent over the period 2011–2014. One of the key ...

World Market for Anti-Infectives: Antifungals, Antibacterials and Antivirals (Treatments for HIV, HBV, HCV, Urinary Tract, Respiratory, Candidiasis and Other Infections) by Kalorama Information
This Kalorama Information report – The World Market for Anti-Infectives - focuses on three key segments of treatment: Antifungals (Allylamines, Azoles, ...

Future Infectious Disease Testing Market: Growth Opportunities, Business Strategies, Market Entry Barriers and Risks by Venture Planning Group
The report identifies the major opportunities for infectious disease testing instrumentation, reagent kits/test panels, consumables, as well as IT and auxiliary products; proposes design criteria ...

See all reports like this >>

The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)

Share this report

Other tasks

Research Assistance

Related Markets

Infectious Diseases Reports

Free Alert Me service